SARS-CoV-2 is transmitted through airborne droplets and tiny particles, making the respiratory system its primary route of infection. Researchers use this to their advantage by designing inhalable drugs comprised of tiny antibodies that protect against SARS-CoV-2. This webinar will explore the world of small, inhalable antibodies and how scientists use this new approach to guard against SARS-CoV-2 infection.
Topics to be covered
Aashish Manglik, MD, PhD
Department of Pharmaceutical Chemistry
University of California, San Francisco
Yi Shi, PhD
Department of Cell Biology
Program for Integrative Systems Biology
Carnegie Mellon University-Pitt Program in Computational Biology
University of Pittsburgh School of Medicine
Drug Discovery News or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.